Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Alumis Inc. (ALMS)

23.41 +0.36 (+1.56%)
As of June 18 at 4:00:00 PM EDT. Market Open.
Trade Alumis on Coinbase
Chart Range Bar
Loading chart for ALMS
  • Previous Close 23.05
  • Open 23.80
  • Bid 17.14 x 200
  • Ask 29.23 x 200
  • Day's Range 22.82 - 24.20
  • 52 Week Range 2.76 - 30.60
  • Volume 1,774,889
  • Avg. Volume 1,330,757
  • Market Cap (intraday) 2.985B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.78
  • Earnings Date (est.) Aug 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 40.10

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

www.alumis.com

225

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ALMS
139.86%
S&P 500 (^GSPC)
9.57%

1-Year Return

ALMS
677.74%
S&P 500 (^GSPC)
25.41%

3-Year Return

ALMS
73.41%
S&P 500 (^GSPC)
70.10%

5-Year Return

ALMS
73.41%
S&P 500 (^GSPC)
80.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.74M
Earnings -93.05M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-100M
-80M
-60M
-40M
-20M
0

Analyst Insights

View More

Analyst Price Targets

25.00
40.10 Average
23.41 Current
55.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/19/2026
Analyst Chardan Capital
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 38 -> 40

Statistics

View More

Valuation Measures

Annual
As of 6/18/2026
  • Market Cap

    2.98B

  • Enterprise Value

    2.50B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    286.21

  • Price/Book (mrq)

    5.26

  • Enterprise Value/Revenue

    297.23

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -58.79%

  • Return on Equity (ttm)

    -64.57%

  • Revenue (ttm)

    8.4M

  • Net Income Avi to Common (ttm)

    -237.42M

  • Diluted EPS (ttm)

    -1.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    522.94M

  • Total Debt/Equity (mrq)

    6.29%

  • Levered Free Cash Flow (ttm)

    -206.75M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

23.41 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: